Solid Biosciences Inc (SLDB)

$9.99 0.17 (1.73%)

16:00 EDT SLDB Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 195.82M

PE Ratio -6.49

EPS -1.54

Volume (Avg. Vol.) 241,191

Day's Range $9.75 - $10.18

52-Week Range $1.81 - $15.05

Dividend & Yield N/A (N/A)

SLDB Stock Predictions, Articles, and Solid Biosciences Inc News

From the Web

Solid Biosciences files to sell 19.69M common shares for holders (NASDAQ:SLDB)

From Seeking Alpha Jan 30, 2024

Solid Biosciences (SLDB) has filed a prospectus for the resale of 19.69M common shares, as indicated in a recent SEC filing.

Solid Biosciences stock rises on FDA orphan status

From Seeking Alpha Jan 12, 2024

Solid Biosciences (SLDB) receives Orphan Drug Designation from the U.S. FDA for its treatment of Duchenne muscular dystrophy (DMD). Read more here.

Solid Biosciences raises $109M through private placement (NASDAQ:SLDB)

From Seeking Alpha Jan 8, 2024

Solid Biosciences (SLDB) has entered into private placement to sell 16,973,103 shares of common stock at a price of $5.53 per share and, in lieu of common stock

Solid Biosciences receives FDA Fast Track designation for Duchenne gene therapy candidate

From Seeking Alpha Dec 7, 2023

Iryna Drozd Solid Biosciences (NASDAQ:SLDB) rose about 9% in premarket trading as the company announced the receipt of Fast Track designation for the U.S.

Solid Biosciences gets FDA okay for clinical testing of DMD gene therapy (SLDB)

From Seeking Alpha Nov 14, 2023

Solid Biosciences (SLDB) stock rallied in after-hours trading on news the FDA had okayed clinical testing of the company's gene therapy for Duchenne muscular dystrophy.

SVB Securities Keeps Their Hold Rating on Solid Biosciences (SLDB)

From TipRanks Nov 10, 2022

In a report released today, Joseph Schwartz from SVB Securities maintained a Hold rating on Solid Biosciences (SLDB – Research Report), with a price target of...

ADVERTISEMENT